Inventiva SA Bets Big on Pivotal MASH Trial

Inventiva SA ((FR:IVA)) has held its Q4 earnings call. Read on for the main highlights of the call.

Inventiva SA’s latest earnings call struck a cautiously optimistic tone, as management highlighted strong execution on its pivotal NATiV3 trial, a reinforced balance sheet, and a tightening strategic focus on its lead MASH drug lanifibranor. While investors must now wait until late 2026 for the decisive Phase III readout, the company argued it is operationally and financially prepared to navigate the extended timeline.

Phase III NATiV3 Enrollment Completed and Well Powered

NATiV3, Inventiva’s global Phase III trial in MASH, completed enrollment in April 2025 with more than 1,000 patients in the main cohort and about 410 in an exploratory F1–F4 cohort. Management stressed that the study is powered above 90% for its composite primary endpoint requiring both fibrosis improvement of at least one stage and MASH resolution, aiming to de‑risk statistical uncertainty.

Top-Line Readout Pushed to Late 2026

The company now guides to a top‑line NATiV3 readout in the fourth quarter of 2026, later than some investors expected. Executives framed the shift as driven by disciplined sequencing of clinical operations and biostatistical work, positioning the data release as a major corporate inflection point rather than a rushed milestone.

Robust Cash Position After 2025 Financings

As of December 31, 2025, Inventiva held EUR 230.9 million in cash, cash equivalents and short‑term deposits, bolstered by two significant 2025 equity raises. The company reported net proceeds of roughly EUR 108 million from a May tranche and EUR 139.4 million from a November U.S. offering, giving investors comfort around near‑term capital needs.

Runway Extends Beyond Phase III Readout

On its current spending plan, Inventiva expects its cash runway to stretch to mid‑first quarter 2027, comfortably beyond the Q4 2026 NATiV3 data. If investors fully exercise a third warrant tranche, the runway could extend to mid‑third quarter 2027, with potential additional proceeds of up to EUR 116 million providing further optionality.

Strategic Focus on Lanifibranor and Asset Monetization

Management underscored a clear pipeline prioritization, with lanifibranor now the central value driver and non‑core assets being monetized. In the fourth quarter of 2025, Inventiva sold global rights to odiparcil to Biossil, a deal that could generate up to around 90 million in future regulatory and commercial milestone payments plus high single‑digit royalties on potential net sales.

Clinical Profile and Phase II Efficacy Signals

Lanifibranor is described as a balanced pan‑PPAR agonist targeting alpha, delta and gamma, designed to address both liver histology and metabolic aspects of MASH. In the earlier Phase IIb NATIVE trial, the 1,200 mg dose delivered a statistically significant 24% treatment effect on the composite endpoint at six months and an approximate 18% fibrosis improvement, supporting Breakthrough Therapy and Fast Track designations.

Metabolic Benefits Support Broader Value Proposition

Beyond liver endpoints, Phase II data showed metabolic improvements including an average HbA1c reduction of about 0.5 percentage points. Triglyceride reductions and higher HDL levels were also observed, which the company believes could be especially relevant in the large subgroup of diabetic F2/F3 patients who face both hepatic and cardiometabolic risks.

Building Organizational, Regulatory and Commercial Muscle

To prepare for potential approval, Inventiva expanded its leadership bench in 2025, adding a Chief Medical Officer and President of R&D, an EVP for Quality and Regulatory Affairs, and a Chief Commercial Strategy Officer. The company said regulatory and quality groundwork, along with early commercial planning, are underway, while keeping the front‑end commercial build lean until data clarity improves.

Operational Rigor and Biopsy Quality Controls

Given the central role of histology, management emphasized strict biopsy quality‑control procedures and blinded reading to safeguard data integrity. The company also highlighted that early termination rates remain below the 30% threshold embedded in its financing covenants, reinforcing confidence in maintaining the trial’s effective power.

Expanding MASH Market with Low Diagnosis and Treatment Rates

Inventiva pointed to a large and still underpenetrated MASH market, estimating about 18 million people in the U.S. alone have the disease. Only around 10% are currently diagnosed, though diagnosis is up roughly 25% compared with 2024, and of those with clinically significant F2/F3 disease, only about 40% are under active care, leaving substantial headroom for future therapy adoption.

Extended Readout Timing Adds Patience Risk

While management framed the Q4 2026 readout as disciplined, the longer timeline introduces an additional waiting period for investors. With NATiV3 representing the key value driver, the extended gap to data raises the sensitivity of the stock to interim news flow and sector sentiment, even as operational execution appears on track.

Conditionality Around Post-Readout Funding

The base runway past the readout is reassuring, but further extension depends on full exercise of tranche‑3 warrants that could raise up to EUR 116 million. Access to this capital is tied to both clinical outcomes and investor behavior, creating contingent financing risk if the Phase III data are equivocal or the market backdrop turns less supportive.

Safety Spotlight on Weight Gain and Fluid Retention

As with other agents with PPAR‑gamma activity, lanifibranor can cause dose‑related weight gain and fluid retention, issues that regulators scrutinize closely. The company noted that weight gain appeared to plateau in prior studies and said no signal of heart failure has emerged so far, but acknowledged this will be a central element of regulatory and labeling discussions.

Competitive Landscape and Need for Strong Effect Size

With Madrigal already in the MASH arena and more entrants expected, Inventiva faces a competitive playing field where differentiation will be crucial. Management suggested that reproducing an approximate 18% fibrosis improvement would represent a compelling benchmark, underscoring how much value hinges on a robust NATiV3 efficacy readout.

Uncertainties Around Effect Size and Placebo Response

The Phase III trial is powered for a more conservative treatment effect than seen in Phase II, reflecting the realities of larger, longer studies. The company also highlighted a 7% placebo fibrosis response in NATIVE and acknowledged that variability in single endpoints, and potential noise in placebo performance, remain key variables for interpreting the eventual readout.

Exploratory F4 Cohort Offers Insight but Limited Power

NATiV3 includes an exploratory group of F1–F4 patients, with about 75 compensated F4 subjects primarily informing safety and pharmacology. This cohort is not statistically powered for efficacy, and management indicated that the timing and depth of F4 analyses may limit near‑term planning for a dedicated outcomes trial in this advanced‑disease population.

G&A Inflation Driven by Noncash Governance Costs

General and administrative expenses reached EUR 47.9 million in 2025, a figure inflated by approximately EUR 20.3 million of noncash share‑based compensation. Management characterized these charges as largely tied to governance and organizational transitions, suggesting that core G&A should normalize once these one‑off effects roll off.

Forward-Looking Guidance and Key Milestones

Inventiva reaffirmed that NATiV3 enrollment is complete, dropout rates remain below the 30% covenant threshold and the 72‑week trial remains on course for a Q4 2026 top‑line release. Financially, the company expects its EUR 230.9 million cash pile to fund operations into mid‑Q1 2027 under current plans, or to mid‑Q3 2027 if tranche‑3 warrants are fully exercised, framing the coming 18–24 months as data‑driven but financially supported.

Looking ahead, Inventiva’s story now centers on disciplined execution and patience as NATiV3 progresses toward its late‑2026 readout. With a sizable addressable market, promising Phase II signals and a balance sheet designed to reach the next major catalyst, the upside is clear, but so are the risks tied to effect size, safety and a competitive MASH landscape that leaves little room for a marginal outcome.